RC1416 not checked
Nanjing RegeneCore Biotech Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
2 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “There are two doses in this part. Each subjects will receive the drug by subcutaneous injection.”In the company’s words, NCT07403487 on ClinicalTrials.gov
- Tested for
- Moderate to Severe Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Main trialPhase 2
- “This study is a phase II study of RC1416 in subjects with severe uncontrolled asthma. The purpose of the study is to evaluate efficacy and safety of RC1416 in subjects with severe uncontrolled asthma.”In the company’s words, NCT07403487 on ClinicalTrials.gov
Other drugs for Moderate to Severe Asthma
- BenralizumabAstraZeneca · Phase 3
- HFA-152aGSK · Phase 3
- MM09Inmunotek S.L. · Phase 3
- TEV-56248Teva Branded Pharmaceutical Products R&D, Inc. · Phase 3
- FF/UMEC/VIGSK · Phase 3
- 6103SBio · Phase 3
Coming up2
- 25 Oct 2027Phase 2 trial completes · ClinicalTrials.gov
- 31 May 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 25 Oct 2027 | Phase II Trial of RC1416 Injection in Asthma | |
| Phase 2Recruiting | 31 May 2028 | Phase II Study of RC1416 Injection in COPD | |
| Phase 1Completed | 14 May 2024 | A Phase I Study of RC1416 Injection | |
| Phase 1Completed | 25 Sep 2025 | A Phase Ib Study of RC1416 Injection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026